FI3793992T3 - Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä - Google Patents

Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä Download PDF

Info

Publication number
FI3793992T3
FI3793992T3 FIEP19731374.5T FI19731374T FI3793992T3 FI 3793992 T3 FI3793992 T3 FI 3793992T3 FI 19731374 T FI19731374 T FI 19731374T FI 3793992 T3 FI3793992 T3 FI 3793992T3
Authority
FI
Finland
Prior art keywords
mmp
sen
patenttivaatimuksen
tarpeessa
olevassa
Prior art date
Application number
FIEP19731374.5T
Other languages
English (en)
Finnish (fi)
Inventor
Wenjin Yang
Kai-Wei Chang
Suying Liu
Cheng-Han Tsai
Original Assignee
Foresee Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Usa Inc filed Critical Foresee Pharmaceuticals Usa Inc
Application granted granted Critical
Publication of FI3793992T3 publication Critical patent/FI3793992T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FIEP19731374.5T 2018-05-15 2019-05-14 Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä FI3793992T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671753P 2018-05-15 2018-05-15
PCT/US2019/032127 WO2019222154A1 (en) 2018-05-15 2019-05-14 Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Publications (1)

Publication Number Publication Date
FI3793992T3 true FI3793992T3 (fi) 2024-04-17

Family

ID=66690981

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP19731374.5T FI3793992T3 (fi) 2018-05-15 2019-05-14 Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä
FIEP19728197.5T FI3793995T3 (fi) 2018-05-15 2019-05-14 Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä

Family Applications After (1)

Application Number Title Priority Date Filing Date
FIEP19728197.5T FI3793995T3 (fi) 2018-05-15 2019-05-14 Matriksin metalloproteinaasin (mmp) estäjiä ja niiden käyttömenetelmiä

Country Status (20)

Country Link
US (6) US11739080B2 (cg-RX-API-DMAC7.html)
EP (4) EP3793992B1 (cg-RX-API-DMAC7.html)
JP (4) JP7343571B2 (cg-RX-API-DMAC7.html)
KR (3) KR102861502B1 (cg-RX-API-DMAC7.html)
CN (3) CN119462623A (cg-RX-API-DMAC7.html)
AU (3) AU2019270975B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020023269A2 (cg-RX-API-DMAC7.html)
CA (2) CA3100319A1 (cg-RX-API-DMAC7.html)
DK (2) DK3793995T3 (cg-RX-API-DMAC7.html)
ES (2) ES2984594T3 (cg-RX-API-DMAC7.html)
FI (2) FI3793992T3 (cg-RX-API-DMAC7.html)
HU (2) HUE066627T2 (cg-RX-API-DMAC7.html)
LT (1) LT3793995T (cg-RX-API-DMAC7.html)
MY (1) MY199200A (cg-RX-API-DMAC7.html)
PL (1) PL3793995T3 (cg-RX-API-DMAC7.html)
PT (2) PT3793995T (cg-RX-API-DMAC7.html)
SG (2) SG11202011318QA (cg-RX-API-DMAC7.html)
SI (1) SI3793995T1 (cg-RX-API-DMAC7.html)
TW (3) TWI827601B (cg-RX-API-DMAC7.html)
WO (2) WO2019222154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532102B2 (en) * 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof
DK4058437T3 (da) 2019-11-14 2025-01-20 Foresee Pharmaceuticals Usa Inc Matrix-metalloproteinase-(MMP)-inhibitorer og fremgangsmåder til anvendelse heraf
JP2024520818A (ja) * 2021-06-08 2024-05-24 フォアシー ファーマシューティカルズ カンパニー リミテッド 急性呼吸促迫症候群を処置するためのmmp阻害薬の使用
KR20240019265A (ko) * 2021-06-08 2024-02-14 포시 파마슈티컬스 컴퍼니 리미티드 Mmp-12 억제제의 안전한 투여
EP4198033A1 (en) 2021-12-14 2023-06-21 Basf Se Heterocyclic compounds for the control of invertebrate pests
WO2023110473A1 (en) 2021-12-14 2023-06-22 Basf Se Heterocyclic compounds for the control of invertebrate pests

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2482618A1 (fr) 1980-05-16 1981-11-20 Inst Corps Gras Iterg Procede de conjugaison catalytique de corps gras polyinsatures, produits obtenus et application
AU1817700A (en) 1998-12-31 2000-07-24 Aventis Pharmaceuticals Inc. 1-carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of mmp-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
AU4882101A (en) 2000-04-28 2001-11-12 Shionogi & Co., Ltd. Mmp-12 inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
MXPA03008180A (es) * 2001-03-15 2003-12-12 Astrazeneca Ab Inhibidores de metaloproteinasa.
ATE445400T1 (de) 2001-05-25 2009-10-15 Bristol Myers Squibb Co Hydantion-derivate als hemmer von matrix- metalloproteinasen
EP1394159A1 (fr) 2002-08-13 2004-03-03 Warner-Lambert Company LLC Nouveaux dérivés de thiophène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
WO2004033632A2 (en) * 2002-10-04 2004-04-22 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
US7132432B2 (en) * 2003-06-05 2006-11-07 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)
ES2364068T3 (es) * 2004-08-19 2011-08-24 Quest Pharmaceutical Services 5-[3-(4-benciloxifeniltio)-fur-2-il]-imidazolin-2,4-diona y sus análogos como inhibidores de macrófago elastasa.
JP5357365B1 (ja) 2011-12-21 2013-12-04 パナソニック株式会社 データ処理装置、データ送信装置、データ処理システム、データ処理方法、及び、データ送信方法
SG11202011318QA (en) * 2018-05-15 2020-12-30 Foresee Pharmaceuticals Usa Inc Matrix metalloproteinase (mmp) inhibitors and methods of use thereof

Also Published As

Publication number Publication date
EP3793995B1 (en) 2024-01-10
US20250115590A1 (en) 2025-04-10
DK3793995T3 (da) 2024-04-08
PT3793992T (pt) 2024-05-13
HUE066627T2 (hu) 2024-08-28
US10851089B2 (en) 2020-12-01
EP4349332A3 (en) 2024-05-15
LT3793995T (lt) 2024-04-25
DK3793992T3 (da) 2024-04-08
EP3793992B1 (en) 2024-01-10
CN112424192B (zh) 2024-11-26
TW202400584A (zh) 2024-01-01
AU2019270975B2 (en) 2023-12-14
TW202003493A (zh) 2020-01-16
US20210214340A1 (en) 2021-07-15
CN119462623A (zh) 2025-02-18
FI3793995T3 (fi) 2024-04-17
TW202002975A (zh) 2020-01-16
KR20250021604A (ko) 2025-02-13
US12258335B1 (en) 2025-03-25
US20190352288A1 (en) 2019-11-21
EP3793992A1 (en) 2021-03-24
ES2978192T3 (es) 2024-09-06
JP2021523240A (ja) 2021-09-02
AU2024200323A1 (en) 2024-02-01
KR20210020897A (ko) 2021-02-24
MY199200A (en) 2023-10-19
AU2019269409B2 (en) 2023-11-23
JP7343571B2 (ja) 2023-09-12
KR20210020011A (ko) 2021-02-23
US11739080B2 (en) 2023-08-29
EP4335499A3 (en) 2024-05-15
CN112424186A (zh) 2021-02-26
US20240018131A1 (en) 2024-01-18
SG11202011318QA (en) 2020-12-30
TWI798435B (zh) 2023-04-11
PT3793995T (pt) 2024-05-02
SI3793995T1 (sl) 2024-05-31
JP7656669B2 (ja) 2025-04-03
US20190352287A1 (en) 2019-11-21
TWI895726B (zh) 2025-09-01
US12215096B2 (en) 2025-02-04
CA3100320A1 (en) 2019-11-21
WO2019222157A1 (en) 2019-11-21
JP7344959B2 (ja) 2023-09-14
KR102861502B1 (ko) 2025-09-18
PL3793995T3 (pl) 2024-05-06
AU2019269409A1 (en) 2021-01-07
KR102761591B1 (ko) 2025-01-31
ES2984594T3 (es) 2024-10-30
EP4349332A2 (en) 2024-04-10
TWI827601B (zh) 2024-01-01
HUE066619T2 (hu) 2024-08-28
CA3100319A1 (en) 2019-11-21
CN112424192A (zh) 2021-02-26
WO2019222154A1 (en) 2019-11-21
EP4335499A2 (en) 2024-03-13
AU2024200323B2 (en) 2025-06-05
JP2023164905A (ja) 2023-11-14
JP2023164924A (ja) 2023-11-14
EP3793995A1 (en) 2021-03-24
BR112020023269A2 (pt) 2021-02-23
SG11202011316RA (en) 2020-12-30
EP4349332B1 (en) 2026-07-15
AU2019270975A1 (en) 2021-01-07
JP2021523241A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
Casey et al. Bank lending constraints, trade credit and alternative financing during the financial crisis: Evidence from European SMEs
Zhou et al. DEA frontier improvement and portfolio rebalancing: An application of China mutual funds on considering sustainability information disclosure
Elshandidy et al. Aggregated, voluntary, and mandatory risk disclosure incentives: Evidence from UK FTSE all-share companies
GB201801679D0 (en) Database transaction log writing and integrity checking
Qiu et al. Do target CEOs trade premiums for personal benefits?
EP3776438A4 (en) BLOCK CHAIN LOAN TRANSACTION SYSTEMS AND PROCEDURES
Bernard et al. Mean–variance optimal portfolios in the presence of a benchmark with applications to fraud detection
Liu et al. Robust multi-period portfolio model based on prospect theory and ALMV-PSO algorithm
ATE519158T1 (de) Wiederherstellung einer fehlgeschlagenen datenübertragung zwischen einem host und einer datenspeichervorrichtung
Hsu et al. Asset allocation strategies, data snooping, and the 1/N rule
Moscone et al. Real estate market and financial stability in US metropolitan areas: A dynamic model with spatial effects
Dufrénot et al. Spillover effects of the 2008 global financial crisis on the volatility of the Indian equity markets: Coupling or uncoupling? A study on sector-based data
Bales et al. Does the source of uncertainty matter? The impact of financial, newspaper and Twitter-based measures on US banks
Jeon et al. Valuing American floating strike lookback option and Neumann problem for inhomogeneous Black–Scholes equation
Chen et al. The white squire defense: Evidence from private investments in public equity
Prajapat A new subclass of close-to-convex functions
Sander et al. The resurgence of cultural borders during the financial crisis: The changing geography of Eurozone cross-border depositing
EP3613000A4 (en) SYSTEMS AND PROCEDURES FOR CONDUCTING TRANSACTIONS USING A REPLACEMENT PIN
Wang et al. Global estimates for non-uniformly nonlinear elliptic equations in a convex domain
EP3818486C0 (en) RECOVERING AN ORIGINAL CARD SECURITY CODE USED IN A CARD-BASED TRANSACTION
Hanson et al. Report writing for Static-99R and Static-2002R
Burlakov et al. E-COMMERCE TOOLS AS A FACTOR IN REDUCING TRANSACTION COSTS AGROFORMATIONS
HK40089736A (en) Neurologic toxicity assessment methods and systems for documenting changes in handwriting
Tandiontong et al. The Effect of The Public Accountant Firm Size, Issuer Size, Company Ownership, and Corporate Governance Implementation on Financial Statements Integrity
Wang Answer to the questions of Yanyan Li and Luc Nguyen in arXiv: 1302.1603